A recent study demonstrated that an interaction between mutant-KRAS signaling in cancer cells and IL-13Rα1 from the tumor micro-environment in preneoplastic lesions and PDAC, which suggests that KRAS drives the expression of cytokine receptors, which in turn are activated by cytokines produced predominantly by infiltrating Th2 cells [27]. This evidence concerns the gene KRAS and cancer.